These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 30843757)
1. Trends in vaccine investment in middle income countries. Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757 [TBL] [Abstract][Full Text] [Related]
2. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries. Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863 [TBL] [Abstract][Full Text] [Related]
3. Costs of vaccine programs across 94 low- and middle-income countries. Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184 [TBL] [Abstract][Full Text] [Related]
4. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030. Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156 [TBL] [Abstract][Full Text] [Related]
5. State of equity: childhood immunization in the World Health Organization African Region. Casey RM; Hampton LM; Anya BM; Gacic-Dobo M; Diallo MS; Wallace AS Pan Afr Med J; 2017; 27(Suppl 3):5. PubMed ID: 29296140 [TBL] [Abstract][Full Text] [Related]
6. Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study. Ikilezi G; Micah AE; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL Lancet; 2021 Nov; 398(10314):1875-1893. PubMed ID: 34742369 [TBL] [Abstract][Full Text] [Related]
7. Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019. Catharina de Beer J; Goto D; Miller-Janson H; Holl R; Bencina G Vaccine; 2022 Sep; 40(39):5691-5700. PubMed ID: 36030126 [TBL] [Abstract][Full Text] [Related]
8. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe. Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171 [TBL] [Abstract][Full Text] [Related]
9. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches. Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157 [TBL] [Abstract][Full Text] [Related]
10. An analysis of government immunization program expenditures in lower and lower middle income countries 2006-12. Nader AA; de Quadros C; Politi C; McQuestion M Health Policy Plan; 2015 Apr; 30(3):281-8. PubMed ID: 24561878 [TBL] [Abstract][Full Text] [Related]
11. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. Levin A; Wang SA; Levin C; Tsu V; Hutubessy R PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002 [TBL] [Abstract][Full Text] [Related]
12. Opportunities to accelerate immunization progress in middle-income countries. Zhu J; Cole CB; Fihman J; Adjagba A; Dasic M; Cernuschi T Vaccine; 2024 Apr; 42 Suppl 1():S98-S106. PubMed ID: 37460357 [TBL] [Abstract][Full Text] [Related]
14. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Brenzel L Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183 [TBL] [Abstract][Full Text] [Related]
15. The equity road ahead for financing non-national immunization program vaccines in China: challenges and opportunities from a qualitative study. Jiang M; Jiang W; Yan X; Ma H; Zhou S; Ying X Int J Equity Health; 2024 Sep; 23(1):193. PubMed ID: 39334358 [TBL] [Abstract][Full Text] [Related]
16. Strengthening vaccination policies in Latin America: an evidence-based approach. Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196 [TBL] [Abstract][Full Text] [Related]
17. School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008-2017. Feldstein LR; Fox G; Shefer A; Conklin LM; Ward K Vaccine; 2020 Jan; 38(3):680-689. PubMed ID: 31679861 [TBL] [Abstract][Full Text] [Related]
18. National vaccine coverage trends and funding in Latin America and the Caribbean. Llau AF; Williams ML; Tejada CE Vaccine; 2021 Jan; 39(2):317-323. PubMed ID: 33288342 [TBL] [Abstract][Full Text] [Related]
19. Income Elasticity of Vaccines Spending versus General Healthcare Spending. Alfonso YN; Ding G; Bishai D Health Econ; 2016 Jul; 25(7):860-72. PubMed ID: 26010073 [TBL] [Abstract][Full Text] [Related]
20. Forecasted trends in vaccination coverage and correlations with socioeconomic factors: a global time-series analysis over 30 years. de Figueiredo A; Johnston IG; Smith DM; Agarwal S; Larson HJ; Jones NS Lancet Glob Health; 2016 Oct; 4(10):e726-35. PubMed ID: 27569362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]